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ttp://dx.doi.org/10.1016/j.ajpath.2014.12.021Ocular infection with herpes simplex virus 1 can result in a chronic immunoinﬂammatory stromal keratitis
(SK) lesion that is a signiﬁcant cause of human blindness. A key to controlling SK lesion severity is to
identify cellular and molecular events responsible for tissue damage and to manipulate them therapeuti-
cally. Potential targets for therapy are miRNAs, but these are minimally explored especially in responses to
infection. Here, we demonstrated thatMir155 expression was up-regulated after ocular herpes simplex virus
1 infection, with the increasedMir155 expression occurring mainly inmacrophages and CD4þ T cells and to a
lesser extent in neutrophils. In vivo studies indicated that Mir155 knockout mice were more resistant to
herpes SK with marked suppression of T helper cells type 1 and 17 responses both in the ocular lesions and
the lymphoid organs. The reduced SK lesion severity was reﬂected by increased phosphatidylinositol-
3,4,5-trisphosphate 5-phosphatase 1 and interferon-g receptor a-chain levels in activated CD4þ T cells in
the lymph nodes. Finally, in vivo silencing of miR-155 by the provision of antagomir-155 nanoparticles to
herpes simplex virus 1einfected mice led to diminished SK lesions and corneal vascularization. In
conclusion, our results indicate that miR-155 contributes to the pathogenesis of SK and represents a
promising target to control SK severity. (Am J Pathol 2015, 185: 1073e1084; http://dx.doi.org/10.1016/
j.ajpath.2014.12.021)Supported by NIH National Institute of Allergy and Infectious Diseases
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result in a chronic tissue-damaging response in the stroma,
which is considered to be largely the consequence of a host
inﬂammatory response to the infection.1 This concept is
strongly supported by animal model studies in which lesions
were shown to be mainly orchestrated by CD4þ T cells with
neutrophils and macrophage largely responsible for the tissue
damage.2e5 Several effective control measures for stromal
keratitis (SK) are suggested.6 These include approaches that
inﬂuence cellular inﬁltration and activation of the proin-
ﬂammatory mediators of SK.6 One potential means of modu-
lating SK lesions that so far has received minimal attention is to
manipulate the expression of miRNA species that affect either
virus or host events during SK.
A prime miRNA candidate for consideration is miR-155
because this miRNA can inﬂuence the expression of several
immune events that contribute to tissue damage.7e10 Forstigative Pathology.
.example, animals unable to produce miR-155 because of gene
knockout may develop milder lesions in some models of
autoimmunity,8,11e13 and suppressing miR-155 expression, as
can be achieved by treatment with antagomirs, holds promise as
a means of therapy for autoimmunity.13 However, the absence
of miR-155 can result in higher susceptibility to some virus
infections and some tumors in part because protective CD8þ
T-cell responses are diminished.14e17 In fact, overexpression of
miRNA can result in enhanced CD8þ T-cellemediated im-
mune protection with some tumors.17
Few studies have focused on the role of miR-155 in situa-
tions in which the immune response to an infectious agent may
Figure 1 Expression of miR-155 after HSV-1 infection. A: WT mice were
infected with HSV-1 RE, and corneas were collected and pooled for miRNA
analysis by RT-qPCR to measure the expression of miR-155 at days 2, 7, and 15
after HSV-1 infection. The expression levels of miR-155 were normalized to
SnoRNA202 by using the DCt calculation. Relative expression was calculated
with the 2DDCt formula. miR-155 levels in mock-infected mice were set to 1
and used for relative fold up-regulation. B: miR-155 expression was measured
by RT-qPCR in sorted neutrophils, macrophages, and CD4þ T cells from WT-
infected corneas at day 15 after infection. CD4þ T cells were isolated from
the lymph nodes of Mir155/ mice at day 15 after HSV-1 infection and served
as a negative control. The expression levels of miR-155 were normalized to
SnoRNA202 by using the DCt calculation. Relative expression was calculated
with the 2DDCt formula. Data are expressed as means  SEM. nZ 9 mice per
group in three independent experiments, each sample is representative of
three corneas (A); n Z 15 mice in two independent experiments (B). Sta-
tistical signiﬁcance was calculated by one-way analysis of variance with
Tukey’s multiple comparison tests. *P 0.05, **P 0.01, and ***P 0.001.
HSV-1, herpes simplex virus 1; RT-qPCR, quantitative real-time RT-PCR;
SnoRNA202, small nucleolar RNA 202; WT, wild-type.
Bhela et albe a principal cause of tissue damage. This is the situation in
ocular lesions of the cornea after HSV-1 infection. Here, we
have compared the disease outcome after HSV-1 infection
in miRNA-155 knockout (Mir155/) mice and in mice in
which miR-155 was suppressed by antagomir therapy with
controls. We show that HSV-1 infection resulted in up-
regulation of miR-155, which was mainly produced by the
inﬂammatory cells and T cells in the cornea. Suppression of
miR-155 production resulted in milder lesions that were
associated with diminished responses of T helper cells type 1
(Th1) and type 17 (Th17) and reduced inﬂammatory cytokine
production. We also demonstrated that miR-155 suppression
resulted in increased phosphatidylinositol-3,4,5-trisphosphate
5-phosphatase 1 (Ship1) and IFN-g receptor a-chain (IFN-
gRa) levels, molecules known to be required for IFN-g
expression and Th1 differentiation.17,18 These results indicate
that miR-155 regulates differentiation and effector function of
Th1 cells. Thus, our results suggest that miR-155 could be a
promising therapeutic target to treat SK.
Materials and Methods
Mice
Female 6- to 8-week-old C57BL/6 mice were purchased from
Harlan Sprague Dawley Inc. (Indianapolis, IN). Mir155/
mice on C57BL/6 background were obtained from The
Jackson Laboratory (Bar Harbor, ME). The mice were housed
in facilities at the University of Tennessee (Knoxville, TN)
approved by the American Association of Laboratory Animal
Care. All investigations followed guidelines of the institutional
animal care and use committee.
Virus
HSV-1 strain RE Tumpey was propagated in Vero cell
monolayers (number CCL81; ATCC,Manassas, VA), titrated,
and stored in aliquots at e80C until used. Ultraviolet (UV)
inactivation of the wild-type (WT) HSV virus (1.5  105
plaque-forming units) was performed for 8 minutes.
Corneal HSV-1 Infection and Scoring
Corneal infections of mice were performed under deep
anesthesia. The mice were lightly scariﬁed on their corneas
with a 27-gauge needle, and a 3-mL drop that contained 104
plaque-forming units of HSV-1 RE was applied to one eye.
Mock-infected mice were used as controls. These mice were
monitored for the development of SK lesions. The SK lesion
severity and angiogenesis in the eyes of mice were examined
by slit-lamp biomicroscopy (Kowa Company, Nagoya, Japan).
The scoring system was as follows: 0, normal cornea;þ1, mild
corneal haze; þ2, moderate corneal opacity or scarring; þ3,
severe corneal opacity but iris visible; þ4, opaque cornea and
corneal ulcer; and þ5, corneal rupture and necrotizing kera-
titis.19 The severity of angiogenesis was recorded as described1074previously.20 According to this system, a grade of 4 for a given
quadrant of the circle represents a centripetal growth of 1.5 mm
toward the corneal center. The score of the four quadrants of the
eye were then summed to derive the neovessel index (range,
0 to 16) for each eye at a given time point.
Subconjunctival Injections
Subconjunctival injections were performed as previously
reported.21 Brieﬂy, these injections were performed with a
2-cm, 32-gauge needle and syringe (Hamilton, Reno, NV)
to penetrate the perivascular region of conjunctiva, and 1-mgajp.amjpathol.org - The American Journal of Pathology
miR-155 and Herpes Stromal Keratitisof scrambled sequence (seq)/antagomir-155 nanoparticles
was administered into the subconjunctival space.
Antagomir Sequences
Antagomir-155 and scrambled seqs were procured from
Ambion (Austin, TX) and were used as previously reported.22
Nanoparticle Preparation
Optimized histidine-lysine polymers were applied for
siRNA deliveries in vitro and in vivo.23 One HK polymer
species, H3K4b, having a lysine backbone with four
branches that contain multiple repeats of histidine and
lysine, was used for packaging siRNAs against miR-155 or
scrambled seqs, with a nanoparticle-to-sequence ratio of
4:1 by mass. The nanoparticles (average size, 150 nm in
diameter) were self-assembled, and these histidine-lysine
polymer siRNA nanoparticles were used in mice.
Murine Treatment with Antagomir-155 Nanoparticles
Mice ocularly infected with HSV-1 RE Tumpey were
separated into two groups. Antagomir-155 nanoparticle
treatment was begun at day 1, with additional doses onFigure 2 Mir155/ mice are resistant to SK. C57BL/6 and Mir155/ mice oc
group of WT mice received IVIGs i.p. at day 4 after infection (WT D4 IVIG). One gr
IVIG), and one group of WT mice received no treatment (WT no IVIG). Disease seve
lesion severity and angiogenesis at day 15 after infection are shown. The experime
from WT (WT D4 IVIG) and Mir155/ (Mir155/ D4 IVIG) mice collected on day 15
corneas were harvested and pooled groupwise for the analysis of various cell typ
Intracellular staining was conducted to quantify Th1 and Th17 cells by stimulating
of CD4þ cells producing IFN-g or IL-17A after stimulation with PMA/ionomycin in t
 D4 IVIG; white bars) mice. Plots shown were gated on CD4þ T cells. The bar grap
and Th17 cells in the corneas of WT (WT D4 IVIG) and Mir155/ (Mir155/ D4 IVI
three independent experiments (C and D). Statistical signiﬁcance was analyzed by
unpaired Student’s t-test (D). **P  0.01, and ***P  0.001. D4, day 4; FACS, ﬂu
simplex virus 1; IFN-g, interferon-g; IVIG, intravenous immunoglobulin; PFU,
keratitis; SSC, side scatter; Th1, T helper cell type 1; Th17, T helper cell type 17;
The American Journal of Pathology - ajp.amjpathol.orgalternate days until day 13 after infection. In another group
of experiments, the antagomir-155 treatment was started at
day 5, with additional doses every day until day 13 after
infection. The control group received nanoparticles that
contained scrambled seqs subconjunctively with the same
regimen for respective experiments. These mice were
carefully followed for the progression of angiogenesis and
SK development.
Administration of IVIGs
Intravenous immunoglobulins (IVIGs; Gammagard Liquid)
was obtained from Baxter (Deerﬁeld, IL). WT and
Mir155/ mice were i.p. injected with IVIG (3.75 mg per
mouse) at day 4 after infection. The dose of IVIG was chosen
to be 3.75 mg per mouse, based on previous studies.24
Flow Cytometry
Single-cell suspensions from cornea, cervical draining
lymph nodes (DLNs), and spleen of mice ocularly infec-
ted with HSV-1 were collected at day 15 after infection.
Aliquots of the above single-cell suspensions were stained
for CD4, CD45, CD11b, and Ly6G cell surface markers.
In apoptosis studies, single-cell suspensions of DLNsularly infected with 1 104 PFU of HSV-1 RE were divided into groups. One
oup of Mir155/ mice received IVIG at day 4 after infection (Mir155/ D4
rity and immune parameters were evaluated at day 15 after infection. A: SK
nt was repeated three times. B: Representative H&E-stained corneal sections
after infection. C and D: Mice were sacriﬁced on day 15 after infection, and
es. C: Representative FACS plots for corneal inﬁltrating total CD4þ T cells.
them with PMA/ionomycin. D: Representative plots (left) show percentage
he cornea of infected WT (WT D4 IVIG; black bars) and Mir155/ (Mir155/
h (right) represents total numbers of corneal inﬁltrating CD4þ T cells, Th1,
G) mice. Data are expressed as means  SEM. nZ 8 to 12 mice per group in
one-way analysis of variance, with Tukey’s multiple comparison tests (A) and
orescence-activated cell sorter; H&E, hematoxylin and eosin; HSV-1, herpes
plaque-forming unit; PMA, phorbol 12-myristate 13-acetate; SK, stromal
WT, wild-type.
1075
Figure 3 Mir155/ mice exhibit reduced frequencies and numbers of
Th1 and Th17 cells in DLNs and spleen after HSV-1 infection. C57BL/6 and
Mir155/ mice were ocularly infected with 1 104 PFU of HSV-1 RE. Both
groups of mice received IVIGs i.p. at day 4 after infection. Mice were
sacriﬁced on day 14 after infection, and single-cell suspensions of the
individual spleen and DLNs were prepared. A: Representative FACS plots
show percentage of CD4þ T cells producing IFN-g or IL-17A after stimu-
lation with PMA/ionomycin in the infected mice from the DLNs and
spleen. Plots shown were gated on CD4þ T cells. B: The bar graph repre-
sents total numbers of CD4þ T cells, Th1, and Th17 cells in the DLNs and
spleen of WT (WT D4 IVIG; black bars) and Mir155/ (Mir155/ D4 IVIG;
white bars) mice. Data are expressed as means SEM. nZ 5 to 6 mice per
group of three independent experiments. Statistical signiﬁcance was
analyzed by the Student’s t-test (unpaired). *P 0.05, ***P 0.001. D4,
day 4; DLN, draining lymph node; FACS, ﬂuorescence-activated cell sorter;
HSV-1, herpes simplex virus 1; IFN-g, interferon-g; IVIG, intravenous
immunoglobulin; PFU, plaque-forming unit; PMA, phorbol 12-myristate
13-acetate; Th1, T helper cell type 1; Th17, T helper cell type 17; WT,
wild-type.
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1076were stained for Annexin V by using a kit from BD
Biosciences (San Jose, CA). In addition, cells were also
costained for CD4, CD44, and viability (Live/Dead
ﬁxable dead cell staining kit; Invitrogen, San Diego, CA).
To enumerate the functionality of CD4þ T cells, intra-
cellular staining was performed. Brieﬂy, 106 cells freshly
isolated from DLNs and spleens or the entire corneal
samples were left untreated or stimulated with phorbol
12-myristate 13-acetate plus ionomycin along with Golgi
plug and incubated for 4 hours at 37C in 5% CO2. After
this period, cell-surface staining was performed, followed
by intracellular cytokine staining with a Cytoﬁx/Cyto-
perm kit (BD Pharmingen, San Diego, CA) to enumerate
the number of IFN-g and IL-17Aeproducing CD4þ T
cells as previously described.25 Finally, the cells were
washed twice and resuspended in 1% paraformaldehyde.
For intracellular staining of Ki-67 (BD Biosciences), cells
were ﬁxed and permeabilized with the FoxP3 Staining
Buffer Set (eBioscience, San Diego, CA) according to the
manufacturer’s recommendations. All stained samples
were acquired with a FACS LSR (BD Biosciences), and
the data were analyzed with the FlowJo software version
8.8.7 (TreeStar Inc., Ashland, OR). For DLN and spleen
samples approximately 200,000 events were recorded. For
corneal samples, depending on the number of corneas
pooled, approximately 300,000 to 1.5  106 events were
recorded.
Puriﬁcation of Macrophages, CD4þ T Cells, and
Neutrophils
Brieﬂy, the excised corneas were pooled and digested with
60 U/mL Liberase (Roche Diagnostics, Indianapolis, IN) for
35 minutes at 37C in a humidiﬁed atmosphere of 5% CO2.
A single-cell suspension was prepared and stained with
different combinations of the following antibodies: anti-
CD4 allophycocyanin, anti-CD45 peridinin-chlorophyll
protein complex, anti-CD11b physphatidylethanolamine,
anti-Ly6G ﬂuorescein isothiocyanate, or F4/80 ﬂuorescein
isothiocyanate for 30 minutes on ice. Approximately 50,000
to 120,000 CD4þ T cells, macrophages (CD45þ, CD11bþ,
F4/80þ), and neutrophils (CD45þ, CD11bþ, Ly6Gþ) were
sorted using a FACSAria cell sorter (BD Biosciences). The
expression of miR-155 was measured on these sorted cells.
In separate experiments, lymph nodes from HSV-
1einfected WT and Mir155/ mice were collected at day
15 after infection. A single-cell suspension was prepared
and stained with different combinations of the following
antibodies: anti-CD4 allophycocyanin, anti-CD44 ﬂuores-
cein isothiocyanate, and anti-CD62L phosphatidylethanol-
amine for 30 minutes on ice. Then, 2.5  105 naive CD4þ T
cells (CD4þ CD62Lhi CD44lo) and activated CD4þ T cells
(CD4þ CD62Llo CD44hi) were sorted using the FACSAria
cell sorter. Purity to an extent of 80% to 90% was achieved.
The expression of miR-155, Ship1, and IFN-gRa were
measured on these sorted cells.ajp.amjpathol.org - The American Journal of Pathology
Figure 4 Mir155/ CD4þ T cells show defec-
tive proliferation but not survival. C57BL/6 and
Mir155/ mice were ocularly infected with
1 104 PFU of HSV-1 RE. Both groups of mice
received IVIGs i.p. at day 4 after infection. Mice
were sacriﬁced on day 14 after infection, and
single-cell suspensions of the individual DLNs and
subpools of corneas were prepared and stained for
Ki-67 and Annexin V. A: Representative FACS
plots, frequencies, and cell numbers of Ki-67þ
CD4þ T cells in the cornea of WT (WT D4 IVIG) and
Mir155/ (Mir155/ D4 IVIG) mice. Plots shown
were gated on CD4þ T cells. B: Representative
FACS plots, frequencies, and cell numbers of Ki-
67þ CD4þ T cells in the DLN of WT (WT D4 IVIG)
and Mir155/ (Mir155/ D4 IVIG) mice. Plots
shown were gated on CD4þ T cells. C: Represen-
tative FACS plots and frequencies of Annexin Vþ
CD4þ CD44hi T cells in the DLNs of WT (WT D4 IVIG)
and Mir155/ (Mir155/ D4 IVIG) mice. Plots
shown were gated on live CD44hi CD4þ T cells.
Data are expressed as means  SEM. n Z 6 to 8
mice per group in two independent experiments.
Statistical signiﬁcance was analyzed by the Stu-
dent’s t-test (unpaired). *P  0.05, **P  0.01,
and ***P 0.001. D4, day 4; DLN, draining lymph
node; FACS, ﬂuorescence-activated cell sorter;
HSV-1, herpes simplex virus 1; IVIG, intravenous
immunoglobulin; PFU, plaque-forming unit; WT,
wild-type.
miR-155 and Herpes Stromal KeratitisQuantiﬁcation of mRNA and miRNA Expression Levels
by Quantitative Real-Time RT-PCR
Total mRNA and miRNA was isolated from corneal and
lymph node cells by using mirVana miRNA Isolation Kit
(Ambion). For RNA, cDNA was made with 500 ng of RNA
by using oligo (dT) primer and ImProm-II Reverse Tran-
scription System (Promega, Madison, WI). For miRNA,
cDNA was made with 5 ng of miRNA by using the TaqMan
miRNA reverse transcription kit (Applied Biosystems,
Foster City, CA) and primers for miR-155 and small
nucleolar RNA 202. TaqMan miRNA Assays (miR-155 and
small nucleolar RNA 202) and TaqMan gene expression
assays [IL-6, IL-1b, IL-17A, IFN-g, chemokine (C-C motif)
ligand 2 (CCL-2), chemokine (C-C motif) ligand 1 (CXCL-
1), Ship1, and IFN-gRa] were purchased from Applied
Biosystems and were used to quantify miRNAs and mRNAs
by using a 7500 Fast Real-Time PCR System (Applied
Biosystems). The expression levels of the target genes were
normalized to b-actin for mRNA and small nucleolar RNA
202 for miRNA with the DCT method, and relative quan-
tiﬁcation between control and infected mice was performed
with the formula 2DDCT  1000.
Statistical Analysis
Statistical signiﬁcance for SK lesion severity and angio-
genesis between the two groups was determined with un-
paired two-tailed Student’s t-test. One-way analysis ofThe American Journal of Pathology - ajp.amjpathol.orgvariance with Tukey’s multiple comparison tests was used
to calculate the level of signiﬁcance for some experiments,
where noted in the results. P  0.05 was considered as
signiﬁcant, and results are expressed as means  SEM. For
all statistical analysis, Prism software version 6.0e (Graph-
Pad Inc., San Diego, CA) was used.
Results
miR-155 Is Up-Regulated in Murine Corneas after
Ocular Infection with HSV
To investigate the potential role of miR-155 in mediating
tissue damage during SK, mice were ocularly infected with
HSV-1, and miRNA levels were quantiﬁed by RT-qPCR in
pools of corneal extracts at various times after infection. The
results showed that miR-155 expression was up-regulated
by day 2 after infection (approximately 10-fold compared
with uninfected corneas) and increased with progression of
diseases at day 7 and day 14 after infection (approximately
20-fold compared with uninfected corneas) (Figure 1A). To
demonstrate if replicating virus was required to up-regulate
miR-155 in eyes, we infected mice with live WT/UV-
inactivated HSV, and miR-155 expression was analyzed.
Our results show that UV-inactivated virus up-regulated the
miR-155 equivalent to live WT virus, indicating that repli-
cating virus is not required for miR-155 induction in eyes
(Supplemental Figure S1). To further determine the cellular
source of SK-induced miR-155, neutrophils, macrophages,1077
Figure 5 Preventive administration of antagomir-155 diminishes SK lesion severity and cellular inﬁltration. C57BL/6 mice were ocularly infected with
1 104 PFU of HSV-1 RE. A: Antagomir-155/scrambled seq (50-AUUUCAUGACUGUUACUGACCU-30) nanoparticle treatment was given subconjunctively. Disease
severity and immune parameters were analyzed at day 14 p.i. B: SK lesion severity and angiogenesis at day 14. C: Representative H&E-stained corneal sections
of scrambled seqetreated and antagomir-155etreated mice were collected on day 14 p.i. Mice were sacriﬁced on day 14 p.i., and corneas were harvested and
pooled groupwise for analysis of various cell types. D: The frequency and total cell number of CD4þ T cells and neutrophils (CD45þ CD11bþ Ly6Gþ) (plot was
gated on CD45þ cells) inﬁltrated in the corneas of control (scrambled seq) and antagomir-155etreated mice. Data are expressed as means  SEM. nZ 8 to 12
mice per group of two independent experiments. Statistical signiﬁcance was analyzed by the Student’s t-test (unpaired). ***P  0.001. H&E, hematoxylin and
eosin; HSV-1, herpes simplex virus 1; PFU, plaque-forming unit; p.i., after infection; seq, sequence; SK, stromal keratitis; SSC, side scatter.
Bhela et aland CD4þ T cells were puriﬁed from WT HSV-1einfected
corneas at day 15 after infection, and miRNA extracts were
tested by RT-qPCR. CD4þ T cells taken from the lymph
node of Mir155/ mice served as a negative control for
these experiments. Data showed miR-155 expression in
neutrophils, macrophages, and CD4þ T cells with the
highest expression being observed in CD4þ T cells and
macrophages (Figure 1B). Collectively, these data indicated
that miR-155 expression was elevated at multiple time
points after ocular HSV-1 infection and that macrophages
and CD4þ T cells were the main source of the miR-155
during the clinical phase of the lesions.
Mir155/ Mice Show Defective CD4þ T-Cell Responses
and Reduced SK Lesion Severity
To further study the role of miR-155 in SK pathogenesis,
the outcome of HSV-1 infection was compared in WT mice1078and mice lacking miR-155 because of gene KO. Because
HSV-1einfected Mir155/ mice usually develop lethal
herpetic encephalitis,26 infected mice were given a source of
anti-HSV antibody (human IVIG) 4 days after infection,
which protects them against encephalitis, but does not
interfere in the WT mice with the extent of SK lesion
severity. Mice in all groups were infected, but levels of SK
disease severity and the extent of angiogenesis were
signiﬁcantly diminished in the Mir155/ mice (Figure 2A).
The administration of IVIG had no effect on the severity of
lesions in the WT mice (Figure 2A). Further documentation
of reduced severity in Mir155/ mice could be shown by
histologic evaluation (Figure 2B) and by quantifying the
extent of the inﬂammatory cellular events in subpools of
corneas taken from WT and Mir155/ mice at day 15 after
infection. The frequencies and numbers of total CD4þ T cells,
Th1 cells, and Th17 cells in the pooled corneal samples were
decreased ﬁvefold to sixfold in the Mir155/ mice comparedajp.amjpathol.org - The American Journal of Pathology
Figure 6 Antagomir-155 treatment reduces cytokine and chemokine
levels in corneas of HSV-1einfected mice. C57BL/6 mice were ocularly
infected with 1 104 PFU of HSV-1 RE. The antagomir-155/scrambled seq
nanoparticle treatment was given subconjunctively every other day starting
day 1 after infection. Mice were sacriﬁced on day 14 after infection, and
corneal extracts were collected for measuring inﬂammatory factors, using
RT-qPCR. A: Relative fold change in mRNA expression of the proin-
ﬂammatory cytokines IL-6, IL-1b, IFN-g, and IL-17 was examined and
compared between control (scrambled seq) and antagomir-155etreated
mice on day 14 after infection. B: Relative fold change in mRNA expression
of chemokines CCL-2 and CXCL-1 was examined and compared between
control (scrambled seq) and antagomir-155etreated mice on day 14 after
infection. The expression levels of different cytokines and chemokines were
normalized to b-actin by using the DCt calculation. Relative expression was
calculated with the 2DDCt formula. mRNA levels for the different cytokines
and chemokines in mock-infected mice were set to 1 and used for relative
fold up-regulation. Data are expressed as means  SEM. n Z 12 mice per
group of two independent experiments; each sample is representative of
four corneas. Statistical signiﬁcance was analyzed by the Student’s t-test
(unpaired). *P  0.05, **P  0.01. CCL-2, chemokine (C-C motif) ligand 2;
CXCL-1, chemokine (C-X-C motif) ligand 1; HSV-1, herpes simplex virus 1;
IFN-g, interferon-g; PFU, plaque-forming unit; RT-qPCR, quantitative real-
time RT-PCR; seq, sequence.
miR-155 and Herpes Stromal Keratitiswith those in the WT mice (Figure 2, C and D). In addition,
analysis of DLNs and spleens of WT and Mir155/ mice
showed twofold to threefold reduced frequencies and total cell
numbers of each population (Figure 3). Taken together the
results indicate that the inﬂammatory response set off by ocularThe American Journal of Pathology - ajp.amjpathol.orginfection with HSV-1 was markedly decreased in mice unable
to express miR-155.
miR-155 Promotes CD4þ T-Cell Proliferation after
HSV-1 Infection
Prior studies have shown that miR-155 targets several
pathways involved in survival and proliferation of effector
T cells.16,27 We determined whether proliferation or
apoptosis could account for the reduced number of effector
T cells in miR-155edeﬁcient mice. WT and Mir155/
mice were ocularly infected with HSV-1 and were treated
with IVIG at day 4 after infection as described inMaterials
and Methods. Mice were sacriﬁced on day 14 after infec-
tion, and proliferation and apoptosis were detected by Ki-
67 and Annexin V staining, respectively. Our results
reveal that Mir155/ CD4þ T cells show signiﬁcantly
reduced proliferative response both in the DLNs and cornea
(Figure 4, A and B). However, no differences were found in
Annexin Vþ CD4þ CD44hi cells in the DLNs of WT and
Mir155/ mice (Figure 4C). Thus, our data suggest that
reduced numbers of Th1 and Th17 responses seen in
Mir155/ mice could be due to defective proliferation of
CD4þ T cells both in the DLNs and the cornea.
Provision of Antagomir-155 Nanoparticles Diminishes
SK Lesion Severity
To evaluate the effect of locally inhibiting miR-155
expression on the extent of SK, mice were subcon-
junctively given antagomir-155, or control scrambled seq
nanoparticles, with treatment starting on either day 1
(preclinical phase) or day 5 (early clinical phase) after
infection (Figure 5A and Supplemental Figure S2A,
respectively). Treatment begun on day 1 resulted in
signiﬁcantly reduced SK scores and angiogenesis in the
antagomir-155etreated mice (Figure 5B). Furthermore,
histopathologic analysis on day 14 after infection showed
that corneas from control scramble seqetreated mice were
inﬂamed and contained a massive inﬁltrate of inﬂamma-
tory cells compared with antagomir-155etreated mice
(Figure 5C). An examination of subpools of collagen-
digested corneas at the termination of experiments on
day 14 revealed that the number and frequencies of in-
ﬂammatory cells (CD4þ T cells and neutrophils) were
signiﬁcantly diminished in the antagomir-155etreated
group compared with the control scramble seqetreated
group (Figure 5D).
In the experiments in which treatment was begun in the
early clinical phase on day 5 after infection when repli-
cating virus is mostly cleared from the HSV-1einfected
corneas, SK and angiogenesis scores were also signiﬁ-
cantly diminished in the antagomir-155etreated mice
(Supplemental Figure S2B). In addition, histopathologic
analysis showed decreased cellular inﬁltration and
inﬂammation in the cornea in the antagomir-155etreated1079
Figure 7 Increased expression of Ship1 and IFN-gRa in Mir155/ activated CD4þ T cells. C57BL/6 and Mir155/ mice ocularly infected with 1 104 PFU
of HSV-1 RE. Both groups of mice received IVIGs i.p. at day 4 after infection. Mice were sacriﬁced on day 14 after infection, and single-cell suspensions of the
individual cervical DLNs were stained for CD4þ, CD44, and CD62L. Cells were then sorted as CD4þ CD44hi CD62Llo (activated) and CD4þ CD44lo CD62Lhi (naive)
from both the HSV-1einfected WT (WT D4 IVIG) and Mir155/ (Mir155/ D4 IVIG) mice at day 14 after infection. A: miR-155 expression by RT-qPCR in
sorted naive and activated cells. Expression levels of miR-155 were normalized to SnoRNA202 by using the DCt calculation. Relative expression was calculated
with the 2DDCt formula. B: Expression of Ship1 mRNA in sorted naive and activated cells by RT-qPCR. C: Expression of IFN-gRa in sorted naive and activated
cells by RT-qPCR. Expression levels of Ship1 and IFN- gRa were normalized to b-actin by using the DCt calculation. Relative expression was calculated with the
2DDCt formula. Data are expressed as means  SEM. n Z 5 to 6 mice per group of two independent experiments. Statistical signiﬁcance was calculated by
one-way analysis of variance with Tukey’s multiple comparison tests. *P  0.05, **P  0.01. D4, day 4; DLN, draining lymph node; FACS, ﬂuorescence-
activated cell sorting; HSV-1, herpes simplex virus 1; IFN-gRa, interferon-g receptor a-chain; IVIG, intravenous immunoglobulin; PFU, plaque-forming
unit; RT-qPCR; quantitative real-time RT-PCR; Ship1, phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1; SnoRNA202, small nucleolar RNA 202; WT,
wild-type.
Bhela et algroup compared with the scramble seqetreated control
group (Supplemental Figure S2C). At the end of experi-
ments on day 14, subpools of corneal collagen digests were
analyzed by ﬂow cytometry to enumerate the numbers
and frequencies of CD4þ T cells and neutrophils
(Supplemental Figure S2D). Both cell populations were
signiﬁcantly reduced in frequency and number in the
recipients of antagomir-155 compared with those that
received the scramble seq control nanoparticles. Taken
together, our results indicated that the silencing of miR-
155 at both preclinical and early clinical stages after
HSV-1 infection diminished pathologic lesions and
leukocyte inﬁltration.Antagomir-155 Nanoparticle Treatment Reduces
Proinﬂammatory Cytokine and Chemokine Levels in the
Corneas of HSV-1eInfected Mice
To assess the effect of antagomir-155 treatment on proin-
ﬂammatory cytokine and chemokine production in SK,
mRNA was prepared from corneal extracts on day 14 after
infection following treatment that was started on day 1 after
infection. Samples from mice treated with antagomir-155
showed a sevenfold to eightfold reduction of proinﬂammatory
cytokines IL-1b and IL-6 and a threefold to fourfold reduction
of IFN-g and IL-17 compared with scrambled seq control-
treated mice (Figure 6A). In addition, levels of chemokines
involved in neutrophil CXCL-1 and monocyte CCL-2 migra-
tion were signiﬁcantly decreased in antagmoir-155etreated
mice (Figure 6B). These data indicate that the provision of
antagomir-155 to HSV-1einfected mice resulted in marked
reduction of proinﬂammatory cytokines and chemokines.1080miR-155 Targets Ship1 and IFN-gRa, which Are
Down-Regulated in Activated CD4þ T Cells
Observations in nonviral systems had indicated that miR-155
might inﬂuence several immune events.7e10 Because CD4þ
T cells of mainly the Th1 phenotype primarily orchestrate
SK, we chose to evaluate the Ship1 and IFN-gRa response
because these are involved in regulating IFN-g expression
and Th1 differentiaton, respectively.2,17,18 Experiments were
performed to measure the effects of miR-155 on levels of
Ship1 and IFN-gRa in naive and activated CD4þ T cells.
Accordingly, WT and Mir155/ mice were ocularly infec-
ted with HSV-1. At day 15 after infection, naive CD4þ T
cells (CD4þ CD62Lhi CD44lo) and activated CD4þ T cells
(CD4þ CD62Llo CD44hi) were sorted from the lymph nodes
and levels of miR-155, Ship1, and IFN-gRawere quantiﬁed.
As expected, there was a minimal level of miR-155 in naive
CD4þ T cells, but activated CD4þ T cells showed an
approximate 20-fold up-regulation (Figure 7A). The mRNA
levels of Ship1 and IFN-gRa were elevated in the activated
CD4þ T cells of Mir155/mice compared with the WT
mice, but no differences were observed in naive CD4þ T cells
among WT and Mir155/ mice (Figure 7, B and C).
Collectively, these results indicated that Mir155 was up-
regulated in activated CD4þ T cells, which correlated with
low Ship1 and IFN-gRa mRNA levels in those T cells.Discussion
In this report, we describe the inﬂuence of miR-155 on
the expression of ocular lesions caused by infection with
HSV-1. The expression of miR-155 was shown toajp.amjpathol.org - The American Journal of Pathology
Figure 8 Illustration of miR-155einduced regulation of inﬂammatory
response during HSV-1 infection. Left panel: Outcome (SK) in HSV-
1einfected WT (Mir155þ/þ) mice. HSV-1 infection leads to ocular inﬁltra-
tion of Th1 and Th17 cells, the major orchestrators of SK. miR-155 degrades
IFN-gRa, Ship1, and conceivably other targets that cause increased
numbers of these cells, along with their heightened effector function. This
increased proinﬂammatory response leads to severe SK. Right panel:
Outcome (SK) in HSV-1einfected Mir155/ mice. HSV-1 infection of
Mir155/ mice leads to higher levels of IFN-gRa and Ship1, resulting in
reduced numbers and functionality of Th1 and Th17 cells, which results in
attenuation of SK lesions. HSV-1, herpes simplex virus 1; IFN-gRa, inter-
feron-g receptor a; Ship1, phosphatidylinositol-3,4,5-trisphosphate
5-phosphatase 1; SK, stromal keratitis; Th1, T helper cell type 1; Th17,
T helper cell type 17; WT, wild-type.
miR-155 and Herpes Stromal Keratitiscontribute to lesion development, because mice unable to
produce miR-155 because of gene KO show signiﬁcantly
reduced severity of SK. That miR-155 was associated
with the development of SK lesions could also be shown
by administration of miR-155 antagomirs in WT mice
early after infection, or around the time when lesions
start to develop. Such mice had suppressed SK lesions.
Cells in SK lesions that were the main producers of miR-
155 were CD4þ T cells and macrophages. The effect of
miR-155 in lesion development was associated with
down-regulation of Ship1 and IFN-gRa, genes involved
in IFN-g expression and Th1 differentiation, respec-
tively.17,18 Increased miR-155 levels led to heightened
production of proinﬂammatory cytokines and chemo-
kines and generation of pathogenic Th1 and Th17 cells
in the eyes during SK. In addition, we could see that
Mir155/ CD4þ T cells showed impaired proliferation
after HSV-1 infection. These overall results are summarized
in Figure 8. The ﬁnding that a normal miR-155 response is
needed to generate consequential SK lesions implies that
modulation of the expression levels could be a usefulThe American Journal of Pathology - ajp.amjpathol.orgtherapeutic strategy to limit the severity of viral-induced
inﬂammatory lesions.
Our study focused on miR-155 because this molecule
was known to be involved in immune and inﬂammatory
reactions,7e10 yet its role during viral infections had
received minimal investigation. Two reports showed that
miR-155 inﬂuenced the magnitude of CD8þ T-cell re-
sponses to a virus infection15,28 and another showed that
diminished miR-155 responses led to more severe virus-
induced lesions in nervous tissue with mice more sus-
ceptible to encephalitis.26 This latter outcome was at
least in part the consequence of diminished CD8þ T-cell
responses known to participate in protection of the cen-
tral nervous system against HSV infection.26 The present
report evaluates the effect of miR-155 expression on the
inﬂammatory consequences of a virus infection, which in
the model investigated occurs because of an inﬂamma-
tory process orchestrated by CD4þ T cells.1,2 Our results
clearly showed that, when miR-155 expression was
suppressed, either because of gene KO or the adminis-
tration of miR-155especiﬁc antagomirs, lesions of SK
were markedly reduced. In fact, our results reﬂect
observations made in some mouse models of autoim-
mune inﬂammation in which lesions were less evident in
situations when miR-155 expression was limited.8,12,13 In
addition, some human autoinﬂammatory lesions appear
to be inﬂuenced by the magnitude of the miR-155
response.9,29 In the viral immunoinﬂammatory model,
the main effect of miR-155 suppression was a signiﬁ-
cantly reduced CD4þ Th1 T-cell reaction along with
diminished noneantigen-speciﬁc inﬂammatory cell
inﬁltration into the cornea, with the latter cells mainly
responsible for tissue damage.3,5 These effects were
apparently the consequence of miR-155 affecting the
levels of Ship1 and IFN-gRa in activated CD4þ T cells,
both of which were signiﬁcantly elevated when miR-155
expression was inhibited. Ship1 is a phosphatase that
negatively regulates cytokine signaling via repression of
the PI3K pathway,30 and its deletion from CD4þ T cells
results in elevated IFN-g expression.31 Thus, in our
system because activated CD4þ T cells in Mir155/
mice showed higher levels of Ship1, it is likely that these
cells would have lower IFN-g expression as shown in
other models.17 In addition, lower IFN-g expression
could also be explained by defective differentiation of
Th1 cells in Mir155/ mice. Regulation of IFN-g
signaling through the IFN-gR is necessary for the dif-
ferentiation of Th1 cells.18,32e34 miR-155, by targeting
IFN-gRa mRNA, might down-regulate the IFNg recep-
tor in activated CD4þ T cells that differentiate into Th1
cells.18 We also observed much higher levels of IFN-
gRa in the activated CD4þ T cells, suggesting defective
Th1 differentiation in the Mir155/ mice. The observed
phenotype of reduction in Th1 and Th17 cell numbers
could also be explained by impaired proliferation and/or
survival of responding T cells. Our data support reduced1081
Bhela et alproliferation of Mir155/ CD4þ T cells rather than
reduced survival on the basis of the use of markers to
indicate such effects.
As shown in some other systems, miR-155 could also
degrade additional crucial targets such as suppressor of
cytokine signaling 1 (SOCS1) that negatively regulates
T-cell function.35 T-cellespeciﬁc deletion of SOCS1
results in multiorgan inﬂammatory lesions, which are
correlated with high levels of IFN-g.35 We measured and
compared the expression of SOCS1 in activated CD4þ T
cells from WT and Mir155/ mice but observed no sig-
niﬁcant differences between the two (data not shown),
suggesting that Ship1 and IFN-gRa were the main targets
of miR-155 in our study. miR-155 was also shown in
in vitro cultures of CD4þ T cells to inﬂuence IL-10 pro-
duction with a higher fraction of Mir155/ CD4þ T cells
producing IL-10.36 However, in the SK situation we failed
to observe enhanced IL-10 production in the corneas of
eitherMir155/ or antagomir-155etreated mice (data not
shown). Nevertheless, we observed signiﬁcantly reduced
numbers of Th17 cells in HSV-infected Mir155/ mice.
This is consistent with the previous reports that show the
role of miR-155 in Th17 cell differentiation.8,37,38 Targets
other than Ship1 and IFN-gRa could be subject to mod-
ulation by miR-155, and this issue is under further
investigation.
It was interesting to observe that, soon after HSV ocular
infection, levels of miR-155 were increased in corneal tis-
sue. The stimulus for this early expression would likely not
be the direct result of viral infection of epithelial cells but
would more likely represent the innate immune-stimulating
activity of the virus. This was supported by our data
showing that UV-inactivated virus could trigger miR-155
up-regulation at day 2 after infection. Thus, HSV-1 is
known to express at least three Toll-like receptor ligand
activities,39e41 and others have documented that Toll-like
receptor stimulation can be a potent agonist for miR-155
production.10 Some herpes viruses do themselves express
several miRNAs, but homologs of miR-155 are not one of
them. In the case of HSV-1, the miRNAs expressed by the
virus are mainly involved in decisions between productive
and latent cycles of replication.42 In the clinical phase of
SK, virus is no longer present in the cornea, and at this time
we could show that the main producers of miR-155 were
proinﬂammatory T cells along with nonspeciﬁc inﬂamma-
tory cells, especially macrophages. Macrophages form a
minor cell population that inﬁltrate corneas during SK.
Some reports suggest that macrophages have antiviral ac-
tivity, which helps in clearing the virus from the cornea,43
whereas other studies show that macrophages are involved
in the development of immunologically driven SK.5
The stimulus for miR-155 production was not identiﬁed,
but it was most likely to include either Toll-like receptor
ligand activity of the virus or cytokines such as IFN-b,
IFN-g, and tumor necrosis factor a that are present during
SK and which are shown in other systems to act as miR-1551082agonists.10 In addition, miR-155 also signals innate cells,
such as neutrophils and macrophages, to produce proin-
ﬂammatory cytokines and chemokines.9,10,44 In cystic
ﬁbrosis patients, for example, increased miR-155 expression
in neutrophils led to increased neutrophil recruitment via
IL-8 activity.9 It was also reported that miR-155emediated
degradation of B-cell lymphoma 6 protein in macrophages
leads to attenuation of NF-kB signaling, resulting in dimin-
ished production of proinﬂammatory cytokines and
chemokines.44 Conversely, miR-155 induced repression of
SOCS1 in macrophages enhanced type I IFN signaling.45 In
a collagen-induced arthritis model, Mir155/ animals
exhibited low levels of inﬂammatory mediators in joints.11
Mir155/ null mice were also seen to be resistant to bacte-
rial keratitis, an effect mediated by miR-155 activity on
macrophages.46 In agreement with these observations, we
could show in our study that diminished miR-155 activity led
to a dampened proinﬂammatory milieu in the eyes. Therefore,
the SK resistance phenotype observed in Mir155/ mice is
likely the consequence of multiple events such as poor
neutrophil and macrophage activity, dampened proin-
ﬂammatory milieu, and attenuated Th1 and Th17 cell
responses. This activity of miR-155 could make it a viable
therapeutic target to treat HSV-induced ocular lesions.
One major rationale for research on miRNAs is the
prospect that manipulating their levels could represent a
viable new approach to therapy. In fact, accumulating evi-
dence indicates that the miRNA environment changes in the
course of an inﬂammatory response with the miRNA spe-
cies present in the proinﬂammatory phase differing from
those prominent during the resolution phase of an inﬂam-
matory response.47,48 It is still not clear if miRNAs are
primarily responsible for this switch of events, but evidence
is accumulating to support the concept.48 In such a scenario,
miR-155 may act as a facilitator of the resolution phase of
an inﬂammatory reaction. Consistently, we showed that the
use of an antagomir to miR-155 at the early clinical phase
diminished the severity of lesions. It seems likely that in a
disease situation manipulating the expression of multiple
miRNA species that are involved in different aspect of
pathogenesis might be the most fruitful approach to therapy.
Consistently, in our preliminary results we have observed
that manipulating miR-155 along with miR-132, a miRNA
involved in angiogenesis,22 may provide more therapeutic
value than using either miRNA alone. Current ongoing
research is evaluating the value of manipulating the levels of
multiple miRNA in an attempt to achieve a more effective
resolution of ocular inﬂammatory reactions.Acknowledgments
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